0001127602-24-010127.txt : 20240314
0001127602-24-010127.hdr.sgml : 20240314
20240314161721
ACCESSION NUMBER: 0001127602-24-010127
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240313
FILED AS OF DATE: 20240314
DATE AS OF CHANGE: 20240314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nicholson Nur
CENTRAL INDEX KEY: 0001827317
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 24750391
MAIL ADDRESS:
STREET 1: APELLIS PHARMACEUTICALS, INC.
STREET 2: 100 5TH AVENUE, 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-03-13
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001827317
Nicholson Nur
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
Chief Technical Officer
0
Common Stock
2024-03-13
4
S
0
7768
57.307
D
59739
D
Common Stock
2024-03-13
4
S
0
3452
58.1335
D
56287
D
This transaction was executed in multiple trades at prices ranging from $56.91 - $57.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $57.92 - $58.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ David Watson, attorney-in-fact for Nur Nicholson
2024-03-14